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Abstract: Eosinophilic esophagitis (EE) is a chronic immune/antigen-mediated esophageal 14 
inflammatory disease for which off-label topical corticosteroids (e.g., budesonide) are widely used 15 
in clinics. In general, thickening excipients are mixed with industrial products to improve the 16 
residence time of the drug on the esophageal mucosa. The compounding procedures are empirically 17 
based, and the composition is not supported on real physicochemical and technological 18 
characterization. The current study aimed to propose a standardized budesonide oral formulation 19 
intended to improve the resistance time of the drug on the esophageal mucosa for EE treatment. 20 
Different placebo and drug-loaded (0.025% w/w) formulations were prepared by changing the 21 
percentage of xanthan gum alone or in ratio 1:1 with guar gum. Both excipients were added in the 22 
composition for their mucoadhesive properties. The formulative space was rationalized based on 23 
the drug physicochemical stability and the main critical quality attributes of the formulation: e.g., 24 
rheological properties, syringeability, mucoadhesiveness and in vitro penetration of budesonide in 25 
porcine esophageal tissue. The obtained results demonstrated that gums allowed to reach a 26 
prolonged residence time. However, the concentration of the mucoadhesive polymer has to be 27 
properly rationalized to permit the syringeability of the formulation and, therefore, easy dosing by 28 
the patient/caregiver.  29 
Keywords: eosinophilic esophagitis; budesonide; xanthan gum; guar gum; mucoadhesion; 30 
esophagus permeability; rheological characterization; pediatric medicine; compounded preparation 31 
 32 
1. Introduction 33 
Eosinophilic esophagitis (EE) is a chronic immune/antigen-mediated esophageal inflammatory 34 
disease associated with esophageal dysfunction resulting from severe eosinophil-predominant 35 
inflammation [1,2]. EE treatment is mainly based on dietary and pharmacological interventions. The 36 
diet of patients having EE is a highly restricted regimen based on the elimination of specific allergen 37 
components for a limited number of weeks. Removal of harmful food allergens results in clinical 38 
remission of EE. After the elimination period, foods can be reintroduced in the diet sequentially in 39 
order to identify food triggers of esophageal eosinophilia and to establish a less restrictive, long-term, 40 
therapeutic diet for effective and least restrictive disease management [3]. Elemental formulas and 41 
other types of elimination diets are a safe and efficacious approach for EE treatment [4] but the severe 42 
restrictions markedly reduce patient compliance [5]. The main drawbacks are the scant palatability 43 
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of the highly restricted diet regimen, the marked weight loss and the high costs for the patient [6]. 44 
Therefore, pharmacological treatment is often necessary. The first choice is based on oral proton 45 
pump inhibitors (PPIs) [7], which are effective, safe and not so expensive for the patients. If the patient 46 
does not respond to PPIs, corticosteroids are good alternative therapeutics, since they can inhibit 47 
maturation and activation of eosinophils through suppression of the release of their stimulating 48 
cytokines. Inhaled budesonide (BU) and fluticasone are the most investigated drugs of this class [8-49 
10]. However, the benefit-risk balance of such medicinal products may be affected by significant 50 
secondary side effects due to the systemic drug absorption after pulmonary administration and by a 51 
low patient adherence due to the complex use of the administration devices (e.g., metered-dose 52 
inhaler). Therefore, the interest in developing topically applied therapeutics has risen [11, 12]. In this 53 
context, off-label topical corticosteroids are frequently used in clinics: patients are trained to swallow 54 
asthma medicinal products originally designed to be inhaled or viscous oral formulations 55 
extemporaneously compounded in pharmacies. Recently, the European regulatory authorities have 56 
authorized an orodispersible tablet loaded with budesonide BU indicated for the treatment of EE in 57 
adults older than 18 years of age. This medicinal product is not suitable for pediatric patients since 58 
they require adjustments in strength and dosage form in comparison to adults [13-15].  59 
When an authorized medicinal product is not available on the market, the compounding of 60 
extemporaneous preparations by the community and hospital pharmacists is crucial to meet the 61 
special needs of patients [16, 17]. The compounding activities should be based on the provisions of 62 
the good compounding practice and other available technical guidelines to assure the required 63 
quality of the magistral preparation [18].  64 
In the case of the BU for EE, a certain number of studies in the literature suggested the clinical 65 
efficacy of viscous preparations. Frequently, they have been prepared by mixing a commercial sterile 66 
suspension of BU to be nebulized, indicated for use in bronchial asthma and in infants and children 67 
with croup, with a thickening agent (e.g., sucralose) [19-21]. Alternatively, cellulose derivatives [22] 68 
or gums [23, 24] was have also been added. Hefner et al. [25] compared the technological 69 
performances of different types of thickening agents like sucralose, xanthan gum or honey, 70 
demonstrating that the gum permitted a better residence time of the active pharmaceutical 71 
ingredients (API) on the esophageal mucosa. However, such pieces of evidence have been obtained 72 
using a medicinal product as an API source instead of the pure API. Although such an approach 73 
seems practical to meet patient’s needs, the use of a medicinal product can determine the presence of 74 
unnecessary excipients in the final preparation and can arise problems of physical compatibility with 75 
all the adopted substances. Moreover, the exact quantitative composition of the medicinal product is 76 
generally unknown. In this light, it is preferable that compounding starts from the raw materials 77 
(pure active principle and excipients). Alternatively, a proprietary excipient mixture can be used as 78 
a formulation base (e.g., Mucolox™) [26]. 79 
The development of standardized formulations can be a valid strategy to support the 80 
pharmacists in their activities, reducing the heterogenicity and uncertainties in compounding 81 
procedures and improving the quality of the final preparation. The availability of well set up and 82 
validated operating procedures is a good way to assure the quality of the magistral preparation. 83 
Aim of this work is to propose a standardized BU oral formulation to improve the residence 84 
time of the drug on the esophageal mucosa. Starting from an already in use formulation in hospital 85 
pharmacy based on xanthan gum, six pharmacists were enrolled in compounding to verify its 86 
reproducibility. On the bases of these results, the formulation and the compounding procedures were 87 
optimized. Considering the interesting evidence reported in the literature on the combined use with 88 
galactomannans, guar gum was selected to compare the performances when in ratio 1:1 vs xanthan 89 
gum alone. The formulative space was rationalized based on the drug physicochemical stability and 90 
the main critical quality attributes of the formulation: e.g., rheological properties, mucoadhesiveness 91 
and in vitro penetration of BU in porcine esophageal tissue.  92 
2. Materials and Methods  93 
2.1. Materials  94 
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Micronized Budesonide (BU) was obtained from Farmabios, Gropello Cairoli, PV, Italy. Guar 95 
Gum (GG, viscosity min 5000 mPas) was kindly gifted by Lamberti spa, Albizzate, VA, Italy. All other 96 
materials were obtained from the named supplier: Xanthan Gum (XG, viscosity more than 1200 97 
mPas), ethylenedinitrilotetraacetic acid disodium salt dihydrate (EDTA), sodium benzoate, sodium 98 
saccharin (Farmalabor, Canosa di Puglia, BAT, Italy); glycerin, sodium dihydrogen phosphate, 99 
orthophosphoric acid. ethanol chemical grade (VWR International, Milan, Italy). 100 
Acetonitrile was HPLC-gradient grade. Purified water was obtained from the purification 101 
system Milli-Q, according to Ph. Eur. 10.0 ed. 102 
2.2. Preparation of oral formulations 103 
The exact amount of glycerin (23.6 ml) was weighed on an analytical balance and poured into a 104 
beaker. Sodium saccharin, EDTA and sodium benzoate were crushed to a fine powder with a mortar 105 
and pestle, then the exact amount of each was weighted and the powders were transferred into the 106 
same beaker. Then XG or the mixture of gums (XG:GG) 1/1 w/w was added. All substances were 107 
mixed to form a homogeneous mixture, then the exact weighted amount of BU (1 mg/4 mL) was 108 
added and again carefully mixed. Purified water was weighed and added, then stirred until a 109 
uniform system was obtained. Different percentages of gums were used: F1P was prepared using XG 110 
2% w/w, F2P with XG:GG 2% w/w, F3P with XG 1.5% w/w and F4P with XG:GG 1.5% w/w. Placebo 111 
formulations were prepared for rheological and technological evaluation. BU was added only to 112 
obtain final loaded formulations F1, F2, and F4. The composition of the formulations is reported in 113 
Table 1. 114 
Table 1. Composition (expressed in grams) of the formulations for 240 ml (4 doses each of 60 ml). 115 
Excipients F1 P  F1 F2 P  F2 F3 P  F4 P  F4 
Budesonide (BU) - 0.06 - 0.06 - - 0.06 
Xanthan gum (XG) 4.80 4.80 2.40 2.40 3.60 1.80 1.80 
Guar gum (GG) - - 2.40 2.40 - 1.80 1.80 
Sodium saccharin 0.24 0.24 0.24 0.24 0.24 0.24 0.24 
Glycerin 29.74 29.74 29.74 29.74 29.74 29.74 29.74 
EDTA 0.24 0.24 0.24 0.24 0.24 0.24 0.24 
Sodium benzoate 0.45 0.45 0.45 0.45 0.45 0.45 0.45 
Water up to (ml) 240 240 240 240 240 240 240 
2.3. Measurements of pH values of the formulations 116 
The pH was measured at time T = 0, using a pHmeter CyberScan 1100 (Eutech Instruments, 117 
Singapore). 118 
2.4. Drug content 119 
About two grams of each formulation was exactly weighed and transferred into a 10 ml amber 120 
glass volumetric flask, bringing up to volume with ethanol. Then the flask was placed in an 121 
ultrasound bath for 20 minutes. The sample was then centrifuged for 5 minutes at 3500 rpm. A portion 122 
of the supernatant was diluted to 2:5 with the mobile phase composed of phosphate buffer pH 3.2: 123 
acetonitrile: ethanol (68:30:2 v/v/v) and analyzed [23]. The remaining supernatant was completely 124 
and accurately removed and 10 ml of fresh ethanol was added. The same extraction procedure was 125 
repeated. 126 
2.5. Stability study 127 
Samples of F1 were stored in an incubator (INCU-Line, VWR International) at 40°C. The drug 128 
content was measured at time T = 0, T = 10, 20, 60 days. Evaluation of BU content was also performed 129 
after T = 30 days at room temperature exposed to light. 130 
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2.6. Determination of rheological properties 131 
The steady and dynamic shear rheological properties of the formulations were carried out using 132 
a controlled stress/strain rheometer Anton Paar MCR 302 equipped with a plate-plate geometry (25 133 
mm diameter and 500 μm gap). The temperature was controlled by a Peltier system on the bottom 134 
plate. Each sample was transferred to the rheometer plate and then was equilibrated at 25 °C for 5 135 
min before steady and dynamic shear rheological measurements were taken. 136 
Steady shear measurements 137 
Flow behavior was evaluated at controlled strain mode to obtain flow rheological data (shear 138 
stress and shear rate) over a shear rate range of 0.1–100 s−1 at 25 °C. The shear stress-shear rate data 139 
were fitted to the well-known power law and Casson models [27] to describe the flow properties of 140 
the samples. 141 
Dynamic shear measurements 142 
Dynamic rheological data were obtained from frequency sweeps over the range of 0.628–62.8 143 
rad s−1 at 2% strain using a small-amplitude oscillatory rheological measurement. The applied 2% 144 
strain was confirmed within the linear viscoelastic region by strain sweep measurement. Frequency 145 
sweep tests were also performed at 25 °C. The RheoCompass software was used to obtain the 146 
experimental data and to calculate the storage (or elastic) modulus (G′), loss (or viscous) modulus 147 
(G″), and loss tangent (tan δ = G″/G′). 148 
2.7. Quantitative determination of syringeability 149 
The measurement of the injection force was performed in compression mode by using a 150 
software-controlled texture analyzer (Instron 5965, ITW Test and Measurement Italia S.r.l., Trezzano 151 
sul Naviglio, Italy). A 10 ml syringe (SOFT-JECT®, VWR International) filled with 9 ml formulation 152 
was positioned in the dynamometer holder, downward needle. The plunger end of the syringe was 153 
placed in contact with a 50 N loading cell. Testing was carried out at the crosshead speed of 0.5 mm/s. 154 
The loading force required to displace the plunger was measured as a function of plunger 155 
displacement. The following parameters were also determined from the force-displacement plot: 156 
• Plunger-stopper break loose force (or “initial glide force”, PBF): the force required to initiate 157 
the movement of the plunger; 158 
• Maximum force (MF): the highest force measured before the plunger finishes its course at the 159 
front end of the syringe; 160 
• Dynamic glide force (DGF): the force required to sustain the movement of the plunger to 161 
expel the content of the syringe. 162 
A schematic representation of the syringeability test setting and a general force-displacement 163 
plot are illustrated in Figure 1. The registered force values were normalized by dividing them for the 164 
cross-sectional area of the cylindrical plunger. The experiments were performed in triplicate. 165 
 166 
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Figure 1. Syringeability test settings and a general F vs displacement curve (PBF: plunger-stopper break 168 
loose force; MF: Maximum force; DGF: Dynamic glide force). 169 
 170 
2.8. Mucoadhesive properties and in vitro esophagus penetration 171 
The in vitro mucosal penetration study was performed adapting the falling liquid technique 172 
described by Cilurzo et al. [28] by using fresh porcine esophageal tissue obtained by a local 173 
slaughterhouse. The mucosa epithelium was separated by specimens of the mucosa by means of a 174 
scalpel. 175 
In-house equipment of three components was built up (Figure 2): (a) in series mucosa supports 176 
set at an angle of 45°; (b) peristaltic pump and (c) collector of fractions. The apparatus was designed 177 
to investigate at the same time the elution of the preparation from the mucosal surface and the drug 178 
penetration into the tissue. 179 
A dose of the selected formulation was deposited onto a 3 x 2 cm mucosal surface corresponding 180 
to a total amount of about 500 mg. Then, the porcine esophageal membrane was placed on the sample 181 
support and pH 6.8 phosphate buffer solution (PBS) was dropped at the rate of 1 ml/min to simulate 182 
the physiological environment and the saliva swallowing. 183 
The residence time was qualitatively estimated by checking the time required for each 184 
formulation to be completely washed away from the surface of the mucosa exposed to the washing 185 
medium. In all cases the latter case, after 30 minutes from the beginning of the experiment, the 186 
apparatus was dismantled, and the applied test sample was peeled away by means of an adhesive 187 
tape strip [28]. The mucosa samples were homogenized, and the amount of the penetrated drug was 188 
extracted with 2 ml methanol and assayed by HPLC. 189 
Pharmaceutics 2019, 11, x FOR PEER REVIEW 6 of 13 
 
 190 
 191 
Figure 2. Apparatus used to evaluate mucoadhesive properties and drug mucosal penetration in vitro. 192 
 193 
2.9. Drug content analysis 194 
The analysis was carried out by HPLC -DAD (Agilent 1100, Agilent, California USA) using an 195 
RP-C18 column (LC 150 x 4.6 mm, 5 µm) with pre-column (Phenomenex, California USA). The mobile 196 
phase was composed of phosphate buffer pH 3.2: acetonitrile: ethanol [29]. The elution was carried 197 
out in gradient (Table 2). The flow rate was 1.7 ml/min, the wavelength was set at 240 nm and the 198 
injection volume at 10 µl. The retention times of the 22R and 22S epimers were 8.8 min and 9.1 min, 199 
respectively. A calibration curve was prepared twice solubilizing in ethanol 10 mg of BU in a 100 ml 200 
volumetric flask. Dilution to obtain 0.1, 0.2, 0.5, 1 and 2 μg/ml concentration were performed (22R: R2 201 
= 0.99930; 22S: R2 = 0.99999).  202 
Table 2. The gradient of the mobile phase. 203 
Time 
(min) 
Phosphate buffer pH 3.2  
(%v/v) 
Acetonitrile 
(% v/v) 
Ethanol 
(% v/v) 
0 - 10 68 → 50 30 → 48 2 
10 - 11 50 48 2 
11 - 16 50 → 68 48 → 30 2 
 204 
2.10 Statistical analysis 205 
Tests for significant differences between means were performed by the Student t-test. 206 
Differences were considered significant at the p<0.05 level. 207 
 208 
3. Results and discussion 209 
Being increased the number of patients having EE, both among adults and young population, 210 
the need to have a standardized topical dosage form is growing, while the widespread habit of mixing 211 
the industrial inhalation product with sweeteners (among them is largely used an artificial sweetener 212 
based on sucralose in maltodextrin/glucose) should not be the first choice. Moreover, to improve the 213 
efficacy of topical corticosteroid administration, it is well established the need for using a viscous 214 
preparation as a vehicle. The proprietary blend Mucolox™ gave good results [26] but it is composed 215 
of a very complex blend. For these reasons, other simpler compositions, already in use in hospital 216 
pharmacies, deserve to be investigated. Quite diffused is the use of viscous formulation containing 217 
XG as a thickening and rheological agent (F1P and F1, Table 1). 218 
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XG is a polysaccharide, largely applied in the food industry. It is highly stable in a wide range 219 
of pH and ionic strength, and, dispersed in water at moderate temperatures, it increases its viscosity 220 
even at low concentration [30, 31]. Temperature preparation can modify the ordered or disordered 221 
state of xanthan chains, as this state is controlled by temperature. 222 
According to the already in use hospital preparation (F1, Table 1), six pharmacists were enrolled 223 
and each of them compounded a batch. At the end of the preparation process, performed at room 224 
temperature, BU was completely dispersed, and the gel-like liquid appeared homogeneous. 225 
Dispersion is due to the low BU solubility in water [32]; good improvement of solubilization could 226 
be obtained using mixtures with ethanol, but this approach must be discarded in the pediatric 227 
population for the limitations in the use of this excipient [33]. The use of glycerin, usually foreseen in 228 
mixture with rheological agents, can contribute in improving BU solubility but this is not enough to 229 
obtain its complete solubilization. The measured pH and drug content are reported in Table 3. pH 230 
values were close to 5 and no significant changes in pH were observed during the storage period. To 231 
exactly measure the drug content, the extraction procedure reported in the literature [23] was 232 
performed twice as a too high amount of BU remained not extracted after a single exposure to solvent. 233 
Variability among operators was is low (Table 3) and immediately after preparation, the mean 234 
content was within the range of acceptability, fixed in ±10% w/w, according to Italian Pharmacopoeia 235 
(BU = 0.262 ± 0.007 mg/ml). The chemical stability study established that the preparation has good 236 
stability as evidenced by the accelerated stability study (storage for over 60 days in an oven incubator 237 
at 40°C; BU = 0.249 ± 0.019 mg/ml) and confirmed the need of handling the preparation by caregivers 238 
or patients avoiding the exposure to light for long period. Indeed, in preparations left at room 239 
temperature over 30 days at the light, more than 50% of drug reduction was observed (BU = 0.103 ± 240 
0.022 mg/ml). The addition of sodium benzoate was added to avoid microbiological contamination 241 
[23]. 242 
Table 3. Chemical characterization of the in-use preparation in the hospital pharmacy (F1: XG 2%). 243 
pH values and drug content at preparation time (T=0) and at the end of the storage period in an 244 
incubator in dark condition (=60 days). Drug content also determined after 30 days at room 245 
temperature exposed at the light.  246 
Batch 
pH 
Micronized BU content 
(mg/mL, n=2)    
T = 0 60 days T = 0 60 days–40°C - dark 30 days–r.t. - light 
1 4.653 4.763 0.273 0.251 0.124 
2 4.630 4.967 0.253 0.228 0.094 
3 4.651 4.706 0.256 0.273 0.105 
4 4.612 4.902 0.266 0.232 0.120 
5 4.606 4.867 0.263 0.244 0.064 
6 4.619 4.681 0.261  0.269 0.112 
To test the technological properties of these systems, their adhesion on the site of action (i.e. 247 
esophageal tissue) or the handling during the application, F1P was modified and a mixture of XG 248 
and GG was used (F2P, Table 1). The addition of galactomannans such as locust bean gum or GG to 249 
a solution of XG at room temperature causes a synergistic increase in viscosity, both at dilute and 250 
concentrated solution [27]. GG is a galactomannan that forms colloidal solutions with elevated 251 
viscosity even at very low concentrations. It is anionic in nature and it remains stable and gives 252 
consistent viscosity over a wide pH range [34]. The viscosity of XG:GG mixtures depends on 253 
operational properties such as the dissolution temperature of gums, polymer concentration and 254 
relationship between XG and galactomannan; depending on these conditions XG:GG solution 255 
mixtures can show a different viscosity. Indeed, being fixed polymer concentration and the ratio 256 
between the gums, in case of extemporaneous preparation, attention must be paid to the temperature 257 
at which each polysaccharide has been solved [35].   258 
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Rheological characterization was performed on the placebo samples based on XG (F1P and F3P) 259 
and XG:GG (F2P and F4P), mixed at room temperature. They have different behaviors: formulations 260 
containing the mixture of the gums have higher shear stress in comparison to those containing only 261 
XG, as already reported in the literature [35], but the shear sensitivity is different (Figure 3). As shown 262 
in Figure 3, XG samples have a linear stress-strain dependence whereas XG:GG samples have a 263 
pseudoplastic behavior, with the stress vs. strain lowering at higher shear rates. When reaching the 264 
highest shear rates, XG:GG 1.5% (F4P) starts having lower stress than XG 2% (F1P). Given the slope 265 
of the curves (i.e. pseudoplastic vs. linear dependence), the behavior is expected to be confirmed at 266 
shear rates higher than 100 s-1, which is the highest that can be reached with the experimental setup 267 
used. Also samples loaded with the active principle were investigated and it was concluded that the 268 
behavior was not influenced by the presence of BU (F1 and F4, Table 4). The pseudo-plastic behavior 269 
of XG:GG samples indicates that physicochemical properties of such formulations are similar to the 270 
ones of linear polymers, i.e. the effect of ionic interactions or other weak bonds (such as hydrogen or 271 
Van del Waals bonds) creating branching and reversible crosslinking between the macromolecular 272 
chains of the gums and other ingredients of the formulations is negligible. This behavior agrees to 273 
that previously observed by Jo et al. on gum mixtures [27]. The same authors evidenced a 274 
pseudoplastic behavior also for the single gums in water solution. In our work, the presence of 275 
glycerin, adding a lot of –OH groups in the formulation, seems to increase the formation of 276 
entanglements and weak bonds in the formulation of XG alone, within the shear range tested. Table 277 
4 shows also the difference in viscosity of the samples at the highest shear rates, confirming that 278 
XG:GG sample viscosity has a far less marked increase than that of XG samples in the 50-100 s-1 range. 279 
This trend is due to the pseudoplastic behavior of XG:GG samples. 280 
 281 
 282 
 283 
Figure 3. Plots of shear stresses versus shear rates of XG and XG-galactomannans mixtures. 284 
A different behavior among the formulations was evidenced also from the performed dynamic 285 
shear measurements. In particular, as shown in Figure 4, a markedly different trend in loss modulus 286 
is visible. In XG:GG samples, the G’’ has only slight variations over the angular frequency range used, 287 
whereas in XG samples it markedly increases as the frequency gets higher, especially at the highest 288 
frequencies. 289 
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 290 
Figure 4. Plots of log ω versus log G″ of XG and XG-galactomannans mixtures. 291 
To identify elastic or viscous behavior, loss tangent values can be calculated. When this value is 292 
smaller than the unit, a sample is more elastic than viscous, and this has been suggested as a 293 
rheological criterion for safe-swallow foods meant for dysphagia [36]. All proposed formulations had 294 
low loss tangent values (Table 4). While loss tangent values for F1P, F2P and F3P were similar, F4P 295 
had a loss tangent significantly higher from the other samples (p<0.05). 296 
The administration of this preparation in very young patients was performed by caregivers, 297 
normally the parents, by means of a big syringe containing 60 ml of the formulation. During this 298 
treatment, some difficulties due to the hard extrusion of the formulation from the syringe were 299 
described by the users. The values measured for the injection force measured for placebo 300 
formulations are reported in Table 4. 301 
Table 4. Viscosity values and injection force measurements of each formulation. 302 
Form. 
Viscosity (Pa*s) Δη  
100 vs 50 s-1 
(%) 
Loss tangent 
Injection force 
50.1 
(s-1) 
70.8 
(s-1) 
100 
(s-1) 
DGF 
(kPa) 
MF 
(kPa) 
PBF 
(kPa) 
F1P 128.15 136.12 144.25 12.6 0.157 ± 0.015 90.01 ± 31.16 77.87 ± 14.50 66.25 ± 5.24 
F1 127.22 135.75 144.83 13.8 0.160 ± 0.016 -* -* -* 
F2P  190.48 197.68 204.46 7.3 0.190 ± 0.040 83.28 ± 8.68 87.08 ± 7.30 58.57 ± 14.13 
F3P  81.57 87.09 92.42 13.3 0.171 ± 0.018 78.08 ± 24.23 85.00 ± 29.67 63.11 ± 19.28 
F4P  130.67 134.89 135.60 
3.8 
0.231 ± 0.045 
121.69 ± 
14.75 
126.39 ± 
14.78 
89.49 ± 27.24 
F4 126.77 128.5 130.02 2.6 0.242 ± 0.047 -* -* -* 
Note: * value not determined 303 
In the force vs. displacement plot of low-viscosity formulations (Figure 1), two different portions 304 
can be identified: the former is related to the force required to displace the plunger, (i.e. PBF). This 305 
event is followed by a plateau (second portion) indicating that the streamline of the formulation 306 
through the needle occurs with a constant force. In this portion, the average load required to sustain 307 
the movement of the plunger to expel the content of the syringe is calculated and reported as DGF.  308 
PBF values were not statistically different among all the tested products (p>0.05), suggesting that 309 
the force required to initiate the movement of the plunger was independent by the formulation. 310 
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The measured extrusion forces showed that F4P required a slightly higher extrusion force (in 311 
terms of DGF) with respect to the other formulations, even if the differences were statistically 312 
significant only in comparison with F2P (p=0.04), and although, from rheology experiments, it was 313 
less viscous than F2P (Figure 3). However, in the shear stress plots, F4P showed also a pseudoplastic 314 
behavior that could not be detected with the syringeability test, probably because the applied force 315 
felt below the useful range of stress. In the case of this pseudoplastic formulation, if we take into 316 
consideration another rheological parameter, the loss tangent value, we can observe that it was higher 317 
for F4P, if compared to the other formulations, suggesting that F4P has a more pronounced viscous 318 
component, even if its overall behavior was mainly elastic. This feature could be responsible for the 319 
relatively higher extrusion forces measured during the syringeability test. However, overall results 320 
show that in any case low forces are needed to extrude the formulations from a syringe, despite the 321 
differences highlighted in the rheological studies.  322 
The chemical and technological effects of the combination of the two gums in the revised 323 
formulations are reported in Table 5. Formulation F3 was considered of less interest because of the 324 
lower shear stress and therefore it was not further investigated. Placebo formulations showed pH 325 
values from 4.975 (F2P) to 5.155 (F4P). As in the case of F1, the addition of BU did not change these 326 
values (Table 5). The formulations can be expected to be non-irritating to the buccal mucosa since the 327 
pH of the esophageal mucosa is reported to be 6.8 in healthy subjects [37].  328 
Table 5. Chemical and technological characterization of the modified preparation. 329 
Batch 
pH 
T=0 
Permanence time 
(min) 
BU penetrated the mucosa 
(mg/g mucosa) (%) 
F1 4.976 28 ± 4 0.790 ± 0.192  0.610 ± 0.132 
F2 5.156 29 ± 2 0.783 ± 0.231 0.562 ± 0.152 
F4 5.068 25 ± 5 0.901 ± 0.367 0.682 ± 0.270 
As far as the mucoadhesive properties are concerned, comparing the formulations, a similar 330 
sliding time from the mucosa samples was observed for all of them. Thanks to the establishment of 331 
interactions between the mucosal layer and the bioadhesive polymer, it was possible to obtain 332 
formulations able to persist into the mucosal surface for about 30 minutes. 333 
The good mucoadhesive properties can be due to the presence of free –COO¯ groups of XG. As 334 
a matter of fact, it is well known that polymers that exhibit a high density of available hydrogen 335 
bonding groups (–COO- groups of XG) can interact more strongly with mucin glycoprotein [3638]. 336 
Moreover, hydrogen bonds are involved in the formation of a strengthened network, thus 337 
contributing to the good bioadhesive strength of the tested formulations. The permanence time onto 338 
the mucosa samples was not influenced by the presence of the drugs into the formulations. Because 339 
of the similar residence time, the percentages of BU penetrated the mucosa by the different 340 
formulations were not significantly different (Table 3). A very small percentage of BU loaded 341 
remained in the mucosae; therefore, to optimize the use of the corticosteroid further evaluations 342 
could be done with formulations containing a reduced amount of the active principle with respect to 343 
that used in the present work. 344 
As it is known, penetration of BU into the mucosa is the final combination of many events; the 345 
physicochemical characteristics of the molecule, and the mucoadhesive properties and viscosity of 346 
the formulation. The advantage of the increased viscosity of the formulation is a reduced outflow 347 
from the mucosal surface, with a consequent increase in the contact time of the drug with the mucous 348 
membrane and therefore in its penetration into the tissue. On the other hand, an excessive viscosity 349 
could obviously create problems in the extrusion from a syringe. The results showed that the use of 350 
the two gums in combination can help to modulate the viscosity of the formulation, however, 351 
remaining within an optimal range such as to be retained onto the mucosal surface for enough time. 352 
Moreover, thanks to its pseudoplastic behavior, the extrusion of such formulations through a syringe 353 
can take place in a feasible way. Unfortunately, this aspect couldn’t be fully investigated by the 354 
Pharmaceutics 2019, 11, x FOR PEER REVIEW 11 of 13 
 
experiments carried out in this work, since the viscosity data should be collected in a higher shear 355 
range to highlight a correlation between syringeability test and viscosity measurements. 356 
4. Conclusions 357 
The prepared formulations showed suitable technological and rheological characteristics for the 358 
treatment of EE. As the addition of GG to XG caused an increase in the viscosity, the mixture of the 359 
gums allows the use of thickening agents in a reduced amount. In this case, results not significantly 360 
different from those measured with the already in use formulation were obtained. Moreover, 361 
considering the limited percentage of BU absorbed in the in vitro penetration experiments, further 362 
evaluations should be carried out to rationalize the drug content and reduce the risk of systemic side 363 
effects. 364 
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